相关临床试验
302
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1899
进行中（未招募）
6
2.0%
已完成
230
76.2%
尚未招募
8
2.6%
招募中
12
4.0%
终止
7
2.3%
Unknown
37
12.3%
撤回
2
0.7%
暂无批准数据
- A new study in The Lancet Microbe calls for integrating female genital schistosomiasis (FGS) screening into existing sexual and reproductive health services across sub-Saharan Africa. - FGS, caused by Schistosoma haematobium, affects at least 40 million women globally and may increase vulnerability to HIV and HPV through chronic inflammation and tissue damage. - Researchers from LSTM, MLW, and LSHTM propose combined HPV–FGS testing from single genital samples, improved healthcare worker training, and AI-supported diagnostic tools. - The emergence of zoonotic and hybrid schistosome species in genital samples raises new concerns about diagnosis, treatment effectiveness, and the need for One Health approaches.
- The IMPALA study demonstrates that injectable HIV treatment with Cabotegravir and Rilpivirine administered every two months is non-inferior to standard oral therapy in African patients with adherence challenges. - The 24-month randomized controlled trial conducted across Kenya, Uganda, and South Africa found the injectable regimen to be safe, well-tolerated, and preferred by most HIV patients. - Results offer renewed hope for addressing the global adherence crisis, with only 71% of people living with HIV achieving viral suppression compared to the UNAIDS 95-95-95 target. - The injectable therapy could help accelerate progress toward reducing HIV-related deaths and improving quality of life for people living with HIV in sub-Saharan Africa.
- Researchers at the University of Sheffield and MRC have identified specific antibodies that protect children against Strep A, a bacterial infection that kills 500,000 people annually worldwide. - The study tracked children in The Gambia and discovered that while maternal protection fades, young children rapidly develop immune responses to parts of the bacteria. - These findings, published in Nature Medicine, represent the first identification of protective antibodies in humans and could enable development of a vaccine to save hundreds of thousands of lives. - The breakthrough addresses a critical knowledge gap that has historically hindered vaccine development against this potentially deadly bacterial infection.
- The World Health Organization has issued its first recommendation for a new malaria vector control tool in over 40 years, endorsing spatial repellents that provide an average 56% protection against mosquito bites. - Clinical trials funded by Unitaid demonstrated that spatial repellents reduced malaria cases by one-third when used alongside insecticide-treated nets, leading to WHO's conditional recommendation in August. - Three spatial repellent products are now available, with Guardian offering up to one year of protection, addressing critical gaps as traditional vector control methods face declining effectiveness due to insecticide resistance. - Unitaid has launched an $18 million investment to expand evidence for spatial repellents as standalone interventions, particularly important as global funding cuts make layering multiple interventions increasingly unaffordable.
- Novartis has received Swiss regulatory approval for Coartem Baby, the first malaria treatment specifically formulated for newborns and infants weighing 2-5 kilograms. - The approval addresses a critical treatment gap, as existing malaria drugs were only tested in children aged 6 months and older, creating dosing risks for babies with immature liver function. - The new treatment will be rolled out in African countries within weeks on a largely not-for-profit basis, targeting regions where malaria caused 597,000 deaths in 2023. - Eight African nations participated in the approval process and are expected to be among the first to access the medicine, which is dissolvable in breast milk and has a sweet cherry flavor.
- England becomes the first country globally to implement a gonorrhoea vaccination program, targeting high-risk populations as infections reach record levels with over 85,000 cases reported in 2023. - The vaccine, repurposed from the meningitis B jab, offers 30-40% protection against gonorrhoea and will primarily be available to gay and bisexual men with multiple partners or previous STI history. - Public health officials hope the vaccination program will help combat the rising threat of antibiotic-resistant gonorrhoea strains, potentially preventing 100,000 cases and saving the NHS nearly £8 million over the next decade.
- The US Agency for International Development (USAID) has suspended all foreign assistance funding, forcing the pause of multiple clinical trials and threatening ongoing research in HIV, tuberculosis, and malaria. - Non-profit organizations like International AIDS Vaccine Initiative (IAVI) have already halted trials, while existing study participants face uncertainty about continued care and follow-up. - Experts warn that the sudden funding gap could lead to increased antimicrobial resistance, setbacks in global health initiatives, and extended drug development timelines unless other sponsors and foundations step in.
- A comprehensive study of over 2.1 million individuals reveals that psoriasis patients do not face significantly higher risks of Alzheimer's disease, contradicting previous conflicting research findings. - Analysis shows a modest increase in vascular dementia risk among psoriasis patients, with a hazard ratio of 1.10, particularly pronounced in severe cases where the risk rises to 1.58. - The 24-year study, conducted by researchers at the London School of Hygiene and Tropical Medicine, demonstrates that psoriasis severity correlates with increased overall dementia risk, though the absolute difference remains small.
- Researchers emulated a clinical trial using real-world data to compare apixaban and warfarin for stroke prevention in atrial fibrillation patients. - The emulation study found similar outcomes for both drugs, differing from the original trial that favored apixaban. - Discrepancies may stem from better warfarin control, suboptimal apixaban dosing, and differences in patient ethnicity and concomitant medication use. - The approach could help assess treatment effects in underrepresented groups and validate trial results in real-world settings.
